Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway
Authors:
Open Access
- 29 February 2024
- journal article
- research article
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (2) , 128-136
Abstract
As the main active ingredient of Astragalus, Astragaloside IV (AS-IV) can ameliorate pulmonary fibrosis. In this experiment, we studied how AS-IV reduces idiopathic pulmonary fibrosis (IPF). Bleomycin (BLM) or TGF‐β1 was treated in mice or alveolar epithelial cells to mimic IPF in vivo as well as in vitro. ASV-IV alleviated levels of inflammatory cytokines and fibrosis markers in IPF model. Through detection of autophagy-related genes, ASV-IV was observed to induce autophagy in IPF. Besides, ASV-IV inhibited miR-21 expression in IPF models, and overexpression of miR-21 could reverse the protective potential of ASV-IV on IPF. PTEN was targeted by miR-21 and was up-regulated by ASV-IV in IPF models. In addition, levels of inflammatory cytokines and fibrosis markers, autophagy, as well as the PI3K/AKT/mTOR pathway regulated by ASV-IV could be neutralized after treatment with autophagy inhibitors, miR-21 mimics, or si-PTEN. Our study demonstrates that ASV-IV inhibits IPF through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway, suggesting that ASV-IV could be acted to be a promising therapeutic method for IPF.Keywords
This publication has 55 references indexed in Scilit:
- Alterations in plasma miR-21, miR-590, miR-192 and miR-215 in idiopathic pulmonary fibrosis and their clinical importanceMolecular Biology Reports, 2022
- miR-21 in EVs from pulmonary epithelial cells promotes myofibroblast differentiation via glycolysis in arsenic-induced pulmonary fibrosisEnvironmental Pollution, 2021
- Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosisFree Radical Biology and Medicine, 2021
- Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potentialBiomedicine & Pharmacotherapy, 2021
- Autophagy, an important therapeutic target for pulmonary fibrosis diseasesClinica Chimica Acta, 2020
- Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects2020
- Regulation of Autophagy by mTOR Signaling Pathway2019
- Biological Functions of Autophagy Genes: A Disease PerspectiveCell, 2019
- Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathwaysBiomedicine & Pharmacotherapy, 2018
- Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K/Akt/mTOR pathwayBiochemical and Biophysical Research Communications, 2018